drug
(foscarbidopa + foslevodopa)
Marketedupdated 6mo agoby $ABBV AbbVie Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.
indications
investigational
Parkinson's Disease
all catalysts(2)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 16, 2027
334 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Jun 10, 2040method-of-use (U-4030)US 12251365
- Oct 21, 2035formulationUS 10174061
- Oct 21, 2035compositionUS 10730895
- Oct 21, 2035compositionUS 9446059
FDA exclusivities (1)
- Oct 16, 2027NPNP334d
News(2)
- AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on dealsStrong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs.biospace · 16d ago
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 3mo ago
Data sources
last refreshed 37m ago
Found something off?
comments(0)
5-min edit window · permanent after that